Benzinga · Oct 19, 2026
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
RX
NASDAQ · RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
Healthcare · Biotechnology
$3.61
Up+$0.05 (+1.39%)
Updated Oct 21, 2026, 12:42 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.83B
- P/E ratio
- -2.94
- Dividend yield
- 0.00%
- 52-week range
- $2.77 – $7.18
- Volume
- 29.94M
- Avg. volume
- 43.4M
Price performance · RXRX
RXRX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
RXRX closed at $3.61 after 21 trading sessions, down 9.07% for the selected period.
- Last close
- $3.61
- Period change
- -9.07%
- Period low
- $3.47
- Period high
- $4.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $3.53 | $3.69 | $3.48 | $3.61 | 29.94M |
| Oct 16, 2026 | $4.11 | $4.185 | $3.44 | $3.465 | 40.72M |
| Oct 15, 2026 | $3.65 | $4.41 | $3.53 | $4.16 | 62.87M |
| Oct 14, 2026 | $3.72 | $3.91 | $3.66 | $3.74 | 18.78M |
| Oct 13, 2026 | $4.01 | $4.05 | $3.82 | $3.835 | 19.76M |
| Oct 12, 2026 | $4.31 | $4.365 | $3.91 | $4.01 | 23.79M |
| Oct 9, 2026 | $4.015 | $4.43 | $3.89 | $4.36 | 35.5M |
| Oct 8, 2026 | $4.19 | $4.20 | $3.79 | $3.95 | 30.9M |
| Oct 7, 2026 | $4.505 | $4.60 | $4.23 | $4.27 | 40.73M |
| Oct 6, 2026 | $4.81 | $5.19 | $4.395 | $4.63 | 71.11M |
| Oct 5, 2026 | $4.16 | $4.935 | $4.0601 | $4.78 | 67.28M |
| Oct 2, 2026 | $4.18 | $4.27 | $4.01 | $4.12 | 18.84M |
| Oct 1, 2026 | $4.07 | $4.17 | $3.96 | $4.07 | 17.48M |
| Sep 30, 2026 | $4.09 | $4.29 | $3.98 | $4.13 | 32.79M |
| Sep 29, 2026 | $3.73 | $4.04 | $3.7225 | $4.03 | 21.56M |
| Sep 28, 2026 | $3.69 | $3.8399 | $3.665 | $3.70 | 13.06M |
| Sep 25, 2026 | $3.89 | $3.90 | $3.70 | $3.74 | 10.48M |
| Sep 24, 2026 | $3.65 | $3.90 | $3.61 | $3.89 | 19.34M |
| Sep 23, 2026 | $4.03 | $4.09 | $3.66 | $3.70 | 23.67M |
| Sep 22, 2026 | $4.00 | $4.16 | $3.90 | $4.05 | 40.46M |
| Sep 21, 2026 | $3.92 | $4.015 | $3.83 | $3.97 | 37.73M |
Latest RXRX news
The latest Smart Investors Daily articles mentioning RXRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RXRX research
Overview
Company profile and research snapshot.
Company profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Needham | Buy | — |
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| May 7, 2026 | Needham | Buy | — |
| Apr 30, 2026 | JP Morgan | Overweight | — |
| Feb 26, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 19, 2026
Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?
Recursion Pharmaceuticals has had a rough ride on the market lately, and the slide raises a simple question for investors who still like the story around its platform and partnerships. Is the current share price adequately grounded in what the company is generating in sales today? Over the past 5 years the share price has fallen 80.5%, which puts the focus squarely on whether the remaining market value lines up with the scale of the business it has built so far. Sanofi’s decision to option...
Yahoo · Oct 19, 2026
Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone
Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial updates and Sanofi optioning a development candidate that triggered a US$10 million milestone within a broader US$144 million received to date. The business also completed a US$200.005 million follow-on equity offering. This reshapes Recursion Pharmaceuticals' funding mix and future dilution profile as it pursues AI-enabled drug discovery. We will look at how Recursion...
Yahoo · Oct 19, 2026
Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone?
Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate from their collaboration, triggering a US$10 million milestone payment and shifting future economics for that program. Despite the Sanofi milestone, Recursion Pharmaceuticals’ recent trading has been rough. The share price is down 16.7% on the day, 20.5% over the past week and 9.5% over 30 days, even after a 19.9% 90 day share price gain and a much weaker 1 year total...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
